Fig. 1.

SLD was chosen as the overarching term to encompass the various causes of steatosis. NAFLD will now be called MASLD, which includes patients with hepatic steatosis and at least one of five cardiometabolic risk factors (adult and pediatric can be found elsewhere (14, 15, 16)). MASH replaces NASH in referring to metabolic dysfunction-associated steatohepatitis. The term steatohepatitis was considered an important pathophysiological concept that should be retained. A new category, MetALD, describes individuals with MASLD who consume more than 140 g/week of alcohol for women and 210 g/week for men. If additional factors contributing to steatosis are discovered, then this aligns with a combined etiology. When it comes to alcohol, the condition is referred to as MetALD or ALD, depending on the severity of alcohol consumption. If no overt cardiometabolic criteria are present, other causes should be ruled out. If none are identified, this is called cryptogenic SLD. Depending on clinical judgment, it may also be considered possible MASLD and would benefit from periodic reassessment on a case-by-case basis. ∗Weekly intake 140–350 g female, 210–420 g male. ∗∗e.g.: lysosomal acid lipase deficiency (LALD), Wilson disease, hypobetalipoproteinemia, and inborn errors of metabolism. ∗∗∗Hepatitis C virus, malnutrition, celiac disease, and human immunodeficiency virus.